4 hours ago
1
Eoneren
Rallybio (NASDAQ:RLYB) shares climbed ~114% in the premarket on Tuesday after the company announced an agreement to sell its ownership interest in REV102, a preclinical asset targeting a rare bone disorder called hypophosphatasia, to its joint venture partner Recursion Pharmaceuticals (
© FBT Company 2025. All rights are reserved
English (US) ·